Unlike the corresponding MMR-proficient cancers, human MMR-deficient cancers respond to immune checkpoint blockade (ICB) (Cercek and Diaz, 2022; Germani and Moretto, 2021; Hewish et al, 2010; Le et al, 2015; Overman et al, 2018). This evidence concerns the gene MRC1 and cancer.